PRESS RELEASE : Formycon Reports on Virtual Annual General Meeting 2020

 
 DGAP-News: Formycon AG / Key word(s): AGM/EGM/Miscellaneous 
Formycon Reports on Virtual Annual General Meeting 2020 
 
2020-12-14 / 09:30 
The issuer is solely responsible for the content of this announcement. 
 
_Press Release // December 14, 2020_ 
 
*Formycon Reports on Virtual Annual General Meeting 2020 * 
 
*- *Shareholders approve all items on the agenda 
 
- Ratification of the actions of the Management Board and Supervisory Board 
by a large majority 
 
- Dr. Olaf Stiller, Peter Wendeln and Klaus Röhrig elected to the 
Supervisory Board 
 
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its Annual 
General Meeting on December 10, 2020 - for the protection of all persons 
involved - in virtual form. 
 
The shareholders were able to follow the virtual Annual General Meeting live 
in picture and sound via the Company's AGM portal. They followed the 
proposals of the Board of Management and Supervisory Board and approved all 
the resolutions proposed by the management with large majorities. Both the 
members of the Board of Management and the Supervisory Board were given a 
vote of confidence with majorities of more than 96 percent each. The 
candidates proposed for election to the Supervisory Board, Dr. Olaf Stiller, 
Mr. Peter Wendeln and Mr. Klaus Röhrig, were elected to the Supervisory 
Board with large majorities. In a subsequent constituent meeting, the 
Supervisory Board re-elected Dr. Olaf Stiller as Chairman and Mr. Peter 
Wendeln as Deputy Chairman. Both enter their third term of office in the 
Supervisory Board of Formycon AG. Hermann Vogt, who had served the Company 
as Deputy Chairman of the Supervisory Board since 2013, did not reapply for 
election. Dr. Stiller expressed his thanks to Mr. Vogt for his many years of 
membership in the Supervisory Board and for his consistently good 
cooperation. 
 
Voting rights could be executed before and during the virtual Annual General 
Meeting by postal vote or by authorizing the Company's proxies. A total of 
around 7.14 million no-par value shares were submitted to the vote, 
corresponding to 64.9 % of the share capital. 
 
Detailed voting results and further information on the 2020 virtual Annual 
General Meeting can be found at 
https://www.formycon.com/en/investor-relations/annual-general-meeting/ [1]. 
 
*About Formycon:* 
Formycon is a leading, independent developer of high-quality 
biopharmaceutical medicines, especially biosimilars. The company focuses on 
treatments in ophthalmology, immunology and on other key chronic diseases, 
covering the entire value chain from technical development to the clinical 
phase III as well as the preparation of dossiers for marketing approval. 
With its biosimilars, Formycon is making a major contribution towards 
providing as many patients as possible with access to vital and affordable 
medicines. Formycon currently has four biosimilars in development. Based on 
its extensive experience in the development of biopharmaceutical drugs, the 
company is also working on the development of antibody-based COVID-19 
compounds. 
 
*About Biosimilars:* 
Since their introduction in the 1980s, biopharmaceuticals have 
revolutionized the treatment of serious diseases such as cancer, diabetes, 
rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming 
years, many of these biotech drugs will lose their patent protection - and 
by 2020, medications with revenues of approximately USD 100 billion will be 
off patent. Biosimilars are follow-on versions of biopharmaceuticals, for 
which exclusivity has expired. They are approved via stringent regulatory 
pathways in highly regulated markets (such as EU, US, Japan, Canada, 
Australia) based on proven similarity of the biosimilar with the originator 
biopharmaceutical reference product. In 2019, global sales of biosimilars 
exceeded USD12 billion. Analysts estimate that this figure could rise to 
around USD 69 billion by 2025. 
 
*Contact:* 
Sabrina Müller 
Senior Manager Corporate Communications and Investor Relations 
Formycon AG 
Fraunhoferstr. 15 
82152 Martinsried/Planegg/Germany 
Phone +49 (0) 89 - 86 46 67 149 
Fax: + 49 (0) 89 - 86 46 67 110 
[e-mail] // www.formycon.com [2] 
 
*Disclaimer:* 
This press release may contain forward-looking statements and information 
which are based on our current expectations and certain assumptions. Various 
known and unknown risks, uncertainties and other factors could lead to 
material differences between the actual future results, financial situation, 
performance of the company, development of the products and the estimates 
given here. Such known and unknown risks and uncertainties comprise, among 
others, the research and development, the regulatory approval process, the 
timing of the actions of regulatory bodies and other governmental 
authorities, clinical results, changes in laws and regulations, product 
quality, patient safety, patent litigation, contractual risks and 
dependencies from third parties. With respect to pipeline products, Formycon 
AG does not provide any representation, warranties or any other guarantees 
that the products will receive the necessary regulatory approvals or that 
they will prove to be commercially exploitable and/or successful. Formycon 
AG assumes no obligation to update these forward-looking statements or to 
correct them in case of developments which differ from those anticipated. 
This document neither constitutes an offer to sell nor a solicitation of an 
offer to buy or subscribe for securities of Formycon AG. No public offering 
of securities of Formycon AG will be made nor is a public offering intended. 
This document and the information contained therein may not be distributed 
in or into the United States of America, Canada, Australia, Japan or any 
other jurisdictions, in which such offer or such solicitation would be 
prohibited. This document does not constitute an offer for the sale of 
securities in the United States. 
 
2020-12-14 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     Formycon AG 
             Fraunhoferstraße 15 
             82152 Planegg-Martinsried 
             Germany 
Phone:       [phone] 
Fax:         [phone] 
Internet:    www.formycon.com 
ISIN:        DE000A1EWVY8 
WKN:         A1EWVY 
Indices:     Scale 30 
Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt 
             (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID: 1154835 
 
End of News DGAP News Service 
 
1154835 2020-12-14 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=8ad328489aaab3c4d514839d767c55e2&application_id=1154835&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0216201e94844788516726bab0fb34a3&application_id=1154835&site_id=vwd&application_name=news

(END) Dow Jones Newswires

December 14, 2020 03:30 ET (08:30 GMT)